Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 7/20 | 0.53 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.38 |
| ▸ | CDC25B | P30305 | 5/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20676828 | 1.00 | SELP (0.53) | SELPTACR1PTPN1CDC25BPTPN2 | |
| SCHEMBL20676803 | 1.00 | SELP (0.53) | SELPTACR1PTPN1CDC25BPTPN2 | |
| SCHEMBL20676866 | 0.96 | SELP (0.51) | SELPTACR1PTPN1CDC25BPTPN2 | |
| SCHEMBL20676865 | 0.96 | SELP (0.51) | SELPTACR1PTPN1CDC25BPTPN2 | |
| SCHEMBL20676776 | 0.96 | SELP (0.51) | SELPTACR1PTPN1CDC25BPTPN2 | |
| SCHEMBL20676861 | 0.96 | SELP (0.51) | SELPTACR1PTPN1CDC25BSIRT2 | |
| SCHEMBL20676780 | 0.96 | SELP (0.51) | SELPTACR1PTPN1CDC25BPTPN2 | |
| SCHEMBL20676812 | 0.95 | SELP (0.51) | SELPTACR1PTPN1CDC25BPTPN2 | |
| SCHEMBL20676772 | 0.95 | SELP (0.51) | SELPTACR1PTPN1CDC25BPTPN2 | |
| SCHEMBL20676869 | 0.94 | SELP (0.55) | SELPTACR1PTPN1CDC25BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | KEIO UNIVERSITY (JP) | 2021-02-16 | — | — | US | disclosed |
| US-20200207798-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | KEIO UNIVERSITY (JP) | 2020-07-02 | — | — | US | disclosed |
| EP-3434684-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | Keio University (JP) | 2019-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207798-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | CD4, NFATC1, PBK | SELP 776/4885TACR1 242/4885PTPN1 1005/4885 |
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | CD4, NFATC1, PBK | SELP 758/4885TACR1 180/4885PTPN1 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.